Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice

PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AEs), and impact of dos...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Roeker, Lindsey E., Fox, Christopher P., Eyre, Toby A., Brander, Danielle M., Allan, John N., Schuster, Stephen J., Nabhan, Chadi, Hill, Brian T., Shah, Nirav N., Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce D., Lamanna, Nicole, Singavi, Arun K., Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Tuncer, Hande H., Winter, Allison M., Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John M., Williams, Annalynn M., Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy A., Mato, Anthony R.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020996/
https://ncbi.nlm.nih.gov/pubmed/31004001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0361
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares